Pfizer Inc. and Boltz, PBC, an applied AI research lab, today announced a strategic collaboration to empower scientists across the company with state-of-the-art biomolecular AI foundation models and generative workflows for small-molecule and biologics design.
Boltz's open-source biomolecular foundation models (Boltz-2, BoltzGen) are very popular AI tools in the pharmaceutical industry for protein design, biomolecular structure prediction, and affinity estimation. The Boltz platform integrates these models with proprietary generative AI workflows, intuitive user interfaces and high-performance compute, making them ready for deployment in preclinical discovery programs.
Under the collaboration, Boltz will refine its latest foundation models on Pfizer's extensive historical data to create state-of-the-art, exclusive models for structure prediction, small-molecule affinity, and biologics design. Additionally, Boltz scientists will work closely with Pfizer's discovery teams to build custom models and workflows for a number of target programs, aiming to accelerate and enhance decision-making in preclinical programs.
Pfizer will retain full ownership of all compounds discovered or developed with the support of the Boltz models and platform.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.